Raymond James Financial Services Advisors Inc. Sells 672 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Raymond James Financial Services Advisors Inc. lessened its position in Henry Schein, Inc. (NASDAQ:HSIC) by 9.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 6,385 shares of the company’s stock after selling 672 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Henry Schein were worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Baystate Wealth Management LLC raised its holdings in Henry Schein by 2,500.0% in the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the period. Neo Ivy Capital Management bought a new position in shares of Henry Schein during the 3rd quarter worth about $46,000. Covestor Ltd increased its holdings in shares of Henry Schein by 88.4% during the 1st quarter. Covestor Ltd now owns 861 shares of the company’s stock worth $75,000 after purchasing an additional 404 shares during the period. Fifth Third Bancorp increased its holdings in shares of Henry Schein by 14.3% during the 3rd quarter. Fifth Third Bancorp now owns 1,744 shares of the company’s stock worth $129,000 after purchasing an additional 218 shares during the period. Finally, Gladius Capital Management LP increased its holdings in shares of Henry Schein by 9.2% during the 3rd quarter. Gladius Capital Management LP now owns 1,989 shares of the company’s stock worth $148,000 after purchasing an additional 167 shares during the period. Institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now owns 73,108 shares in the company, valued at $5,430,462.24. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Jefferies Financial Group boosted their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, March 6th. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b-” rating in a report on Monday, February 26th. Piper Sandler lifted their target price on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Monday, February 26th. Finally, SVB Leerink started coverage on shares of Henry Schein in a research report on Monday, February 26th. They set a “market perform” rating and a $78.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Henry Schein presently has a consensus rating of “Hold” and an average target price of $81.09.

Henry Schein Price Performance

NASDAQ:HSIC opened at $70.86 on Friday. The firm has a market cap of $9.10 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 1.74 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $85.39. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $74.37 and its two-hundred day moving average price is $72.47.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). The firm had revenue of $3.02 billion during the quarter, compared to analyst estimates of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. Henry Schein’s quarterly revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.21 earnings per share. On average, equities analysts anticipate that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.